Skip to main content

BREAST: ATEMPT 2.0

Trial ID
NCT04893109
Trial Sponsor
Dana-Farber Cancer Institute

A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab Versus Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-positive Breast Cancer

ANNOUNCEMENT: We no longer accept cash payments.

X

By using this website, you agree to the use of cookies and our privacy policy.

X